A prospective study on the safety of sublingual immunotherapy in pregnancy

Background The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported. Methods One hundred and fifty‐five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 1...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 2012-06, Vol.67 (6), p.741-743
Main Authors: Shaikh, W. A., Shaikh, S. W.
Format: Article
Language:English
Subjects:
Administration, Sublingual
Adult
Albuterol - adverse effects
Allergens - administration & dosage
Allergens - adverse effects
Biological and medical sciences
Bronchodilator Agents - adverse effects
Budesonide - adverse effects
Dermatology
Desensitization, Immunologic - methods
Female
Fetus - drug effects
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Immunotherapy
Medical sciences
Patient safety
Pregnancy
Pregnancy Complications - epidemiology
safety
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Sublingual
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported. Methods One hundred and fifty‐five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty‐four patients received sublingual immunotherapy for the first time during pregnancy. Follow‐up data were analysed with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. Two control groups did not receive immunotherapy; group A (85 patients) received budesonide 400 μg twice daily and group B (40 patients) received rescue salbutamol inhalation. All three groups were on appropriate avoidance measures. Results Six‐year follow‐up data for the sublingual immunotherapy group revealed an incidence of complications less than that in the general population and a higher incidence of complications in both control groups. Conclusions This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient.
ISSN:0105-4538
1398-9995
DOI:10.1111/j.1398-9995.2012.02815.x